Hiroko Hasegawa

1.3k total citations
99 papers, 905 citations indexed

About

Hiroko Hasegawa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Hiroko Hasegawa has authored 99 papers receiving a total of 905 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Hiroko Hasegawa's work include Colorectal Cancer Treatments and Studies (26 papers), Gastric Cancer Management and Outcomes (19 papers) and Cancer Treatment and Pharmacology (10 papers). Hiroko Hasegawa is often cited by papers focused on Colorectal Cancer Treatments and Studies (26 papers), Gastric Cancer Management and Outcomes (19 papers) and Cancer Treatment and Pharmacology (10 papers). Hiroko Hasegawa collaborates with scholars based in Japan, United States and Belgium. Hiroko Hasegawa's co-authors include Katsuhiko Suzuki, Kyosuke Tsuda, Shigeo Katsumura, Tetsuya Yamamoto, Toshikazu Hakogi, Shigeyuki Nakaji, Yoshihiro Satō, Toshihiko Okamoto, Yutaka Kawazoe and Mitsutaka Natsume and has published in prestigious journals such as Journal of Clinical Oncology, The American Journal of Cardiology and Annals of Oncology.

In The Last Decade

Hiroko Hasegawa

87 papers receiving 874 citations

Peers

Countries citing papers authored by Hiroko Hasegawa

Since Specialization

Citations

This map shows the geographic impact of Hiroko Hasegawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroko Hasegawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroko Hasegawa more than expected).

Fields of papers citing papers by Hiroko Hasegawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroko Hasegawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroko Hasegawa. The network helps show where Hiroko Hasegawa may publish in the future.

Co-authorship network of co-authors of Hiroko Hasegawa

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroko Hasegawa. A scholar is included among the top collaborators of Hiroko Hasegawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroko Hasegawa. Hiroko Hasegawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A case of post-outbreak acute hepatitis a in a Japanese man who have sex with men infected with RIVM-HAV16-090 strain 2025 ·Journal of Infection and Chemotherapy ·(unknown), Satoshi Tanaka, Tatsuya Shirai, Naomi Sakon, Satoshi Harada, A. Kitagawa, (unknown), (unknown), Nobuyasu Fukutake, Hiroko Hasegawa, Shunsuke Yamamoto, Yuko Sakakibara, Ryotaro Sakamori	1
2	Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program 2024 ·Clinical Colorectal Cancer ·Daisuke Kotani, Atsuo Takashima, Takeshi Kato, Taroh Satoh, Toshiki Masuishi, Yoshito Komatsu, Manabu Shiozawa, (unknown), Naoki Izawa, Shinji Takeuchi, Hideaki Bando, Satoru Iwasa, Hiroko Hasegawa, (unknown), Hiroya Taniguchi, (unknown), (unknown), Chiaki Inoue, Takayuki Yoshino	3
3	Impact of stroke volume assessment by three-dimensional transesophageal echocardiography on the classification of low-gradient aortic stenosis 2024 ·Journal of Echocardiography ·(unknown), (unknown), (unknown), Hiroko Hasegawa, Takafumi Yamane, Takahiro Shiota	0
4	P-23 Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study 2023 ·Annals of Oncology ·Takeshi Kato, (unknown), Atsuo Takashima, Taroh Satoh, (unknown), Yoshito Komatsu, Manabu Shiozawa, Taito Esaki, (unknown), Satoshi Takeuchi, Hideaki Bando, Satoru Iwasa, Hiroko Hasegawa, Tomohiro Yamaguchi, (unknown), Satoshi Yamada, Takayuki Yoshino	1
5	Echocardiographic Characteristics of Left and Right Ventricular Longitudinal Function in Patients With a History of Cardiac Surgery 2023 ·The American Journal of Cardiology ·(unknown), (unknown), (unknown), Hiroko Hasegawa, (unknown), Florian Rader, Robert J. Siegel, Takahiro Shiota	2
6	Effect of right ventricular free wall longitudinal strain on all-cause death in patients with isolated severe tricuspid regurgitation and atrial fibrillation 2023 ·Frontiers in Cardiovascular Medicine ·(unknown), (unknown), Takafumi Yamane, Hiroko Hasegawa, (unknown), Takahiro Shiota	2
7	Evaluation of the photosensitizer activity of hydrophobic phosphorus(V)porphyrins using the absorption spectral change of 1-benzyl-1,4-dihydronicotinamide 2023 ·Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy ·Hiroko Hasegawa, Kazutaka Hirakawa	1
8	Long-Term Impact of Small Mitral Valve Orifice Area after Transcatheter Edge-to-Edge Mitral Valve Repair on Clinical Outcome: A Three-Dimensional Echocardiography Study 2023 ·Journal of the American Society of Echocardiography ·Shunsuke Kagawa, Hiroko Hasegawa, (unknown), Takafumi Yamane, (unknown), Dhairya Patel, (unknown), Navjot Sekhon, (unknown), Tarun Chakravarty, Moody Makar, Raj Makkar, Takahiro Shiota	3
9	Determinants of Greater Peak radiation skin dose in percutaneous coronary intervention for chronic total occlusion 2020 ·Journal of Cardiology ·Kei Yamamoto, Kenichi Sakakura, (unknown), Hiroko Hasegawa, Takunori Tsukui, Masaru Seguchi, Yousuke Taniguchi, Hiroshi Wada, Shin‐ichi Momomura, Hideo Fujita	5
10	A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial 2019 ·Cancer Chemotherapy and Pharmacology ·Kazuhiro Nishikawa, Kenta Murotani, Kazumasa Fujitani, (unknown), Yusuke Akamaru, Shinya Tokunaga, Masakazu Takagi, Shigeyuki Tamura, Naotoshi Sugimoto, (unknown), Takaki Yoshikawa, (unknown), Masato Nakamura, Hiroko Hasegawa, Satoshi Morita, Yumi Miyashita, Akira Tsuburaya, Junichi Sakamoto, Toshimasa Tsujinaka	4
11	Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site 2018 ·Clinical Oncology ·Hiroko Hasegawa, Masashi Ando, Yasushi Yatabe, Seiichiro Mitani, Kazunori Honda, Toshiki Masuishi, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Takashi Ura, Kei Muro	9
12	Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody 2017 ·Oncology ·Hiroko Hasegawa, Hiroya Taniguchi, Seiichiro Mitani, Toshiki Masuishi, Azusa Komori, Yukiya Narita, Shigenori Kadowaki, Takashi Ura, Masashi Ando, Yasushi Yatabe, Kei Muro	6
13	169P Serum CA19-9 response is an early predictive marker for the efficacy of regorafenib in refractory metastatic colorectal cancer 2015 ·Annals of Oncology ·(unknown), Hiroya Taniguchi, Yosuke Kito, Satoshi Hamauchi, Toshiki Masuishi, Hiroko Hasegawa, Seiichiro Mitani, Yukiya Narita, Shigenori Kadowaki, Takashi Ura, Masashi Ando, Keita Mori, Hirofumi Yasui, Kei Muro, Kentaro Yamazaki	0
14	Administration of low‐dose epoetin‐alpha facilitates adherence to ribavirin in triple therapy with pegylated interferon‐alpha‐2b and telaprevir 2013 ·Hepatology Research ·Hisashi Ishida, Sadatsugu Sakane, (unknown), (unknown), Keiichi Kimura, Aya Sugimoto, (unknown), Takeshi Tamura, (unknown), Ryuichiro Iwasaki, Hiroko Hasegawa, Yuko Sakakibara, Takuya Yamada, (unknown), Eiji Mita	5
15	Optimal indications for second-line chemotherapy in advanced gastric cancer 2012 ·Anti-Cancer Drugs ·Hiroko Hasegawa, Kazumasa Fujitani, (unknown), Motohiro Hirao, Eiji Mita, Toshimasa Tsujinaka	8
16	A Reproducibility Method to Test Lip-Closing Strength in Preschool Children 2010 ·CRANIO® ·(unknown), Issei Saitoh, Emi Inada, (unknown), Yoko Iwase, Yoshihiko Takemoto, Chiaki Yamada, Tomonori Iwasaki, Hiroko Hasegawa, Naoko Kubota, Tomoya Murakami, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	11
17	Effect of S-1 Adjuvant Chemotherapy on Survival following Recurrence and Efficacy of First-Line Treatment in Recurrent Gastric Cancer 2010 ·Chemotherapy ·Hiroko Hasegawa, Kazumasa Fujitani, Yukinori Kurokawa, Motohiro Hirao, (unknown), Eiji Mita, Toshimasa Tsujinaka	7
18	Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer 2010 ·European Journal of Surgical Oncology ·Yoshiyuki Ishii, Hiroko Hasegawa, Takeshi Endo, Koji Okabayashi, Hiroki Ochiai, Konosuke Moritani, Masahiko Watanabe, Yuko Kitagawa	51
19	A case of ectopic hepatocellular carcinoma with bone metastasis 2009 ·Kanzo ·(unknown), Eiji Mita, Changho Song, Takashi Ohta, Hiroko Hasegawa, (unknown), (unknown), Noriyoshi Kuzushita, (unknown), Masanori Tsujie, Atsushi Miyamoto, Keiji Yamamoto, Shoji Nakamori, Michio Kato	3
20	[Dietary patterns and intake of nutrients, energy, and dietary fiber in medical students]. 1996 ·PubMed ·Shigeru Aoki, Tetsuya Endo, Hiroko Hasegawa, Shigeyuki Nakaji, K. Sugawara, Mamoru Totsuka	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact